Journals / Harran Üniversitesi Tıp Fakültesi Dergisi / 2014 / Cilt: 11 - Sayı: 1

Tümör nekrozis faktör alfa antagonistleri ile tedavi edilen hastalarda latent tüberküloz prevelansı değerlendirilmesi

The assessment of latent tuberculosis prevalence in patients treated with tumor necrosis factor alpha antagonists

Pages
45–52
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The number of patients with AS in patients with PPD ≥induration 5 mm (n=51, 81%) is significantly higher than the number of patients with AS in patients with ≥PPD induration

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine, which plays an importantrole in the pathogenesis of several inflammatory diseases such as ankylosing spondylitis (AS), rheumatoidarthritis (RA) and psoriatic arthritis (PsA).
📊
Key Findings & Data:An increased incidence of tuberculosis in patients under anti-TNF-α therapy has beenreported.
💡
Conclusion & Impact:The number of patients with AS in patients with PPD ≥induration 5 mm (n=51, 81%) is significantly higher than the number of patients with AS in patients with ≥PPD induration
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background: Tumor necrosis factor-α (TNF-α) is a proinflammatory cytokine, which plays an importantrole in the pathogenesis of several inflammatory diseases such as ankylosing spondylitis (AS), rheumatoidarthritis (RA) and psoriatic arthritis (PsA). Anti-TNF-α therapy is now widely used for treatment ofinflammatory diseases. An increased incidence of tuberculosis in patients under anti-TNF-α therapy has beenreported. The aim of this study was to investigate the prevalence of latent tuberculosis in patients treated withan anti-TNF-α agent.Methods: Eighty three patients under anti-TNF-α treatment referring to the Rheumatology outpatient clinicenrolled in the study. Tuberculin skin test (PPD) and chest x-ray are performed. An induration of 5 mm ormore is defined as latent tuberculosis. Patients with latent tuberculosis are treated with isoniazid (INH) 300mg/day during 9 months.Results: Mean age of the 83 patients was 37.59±10.80 years; the average duration of illness was 9.82±7.08years. The primary disease was AS (n=62), RA (n=16), and PsA (n=5). The patients were treated withdifferent anti-TNF-α agents (etanercept n=30, adalimumab n=30, infliximab n=21, and golimumab n=2).PPD induration of 5 mm or more was measured in 63 (76%) of 83 patients. INH prophylaxis was started in 76of the patients including 13 patients with PPD induration < 5mm due to increased risk of tuberculosis (familyhistory, working as a health professional, history of infected with mycobacterium tuberculosis). The numberof male patients (76%) with PPD induration 5 mm is significantly higher than the number of female patients ≥(24%) with PPD induration 5 mm (p=0.026). The number of patients with AS in patients with PPD ≥induration 5 mm (n=51, 81%) is significantly higher than the number of patients with AS in patients with ≥PPD induration

Özet

Amaç: Tümör nekrozis faktör- α (TNF-α) ankilozan spondilit (AS), romatoid artrit (RA) ve ps öriatik artrit(PsA) gibi birçok inflamatuar hastalık patogenezinde rol oynayan bir proinflamatuar sitokindir. Anti-TNF-αtedavisi inflamatuar hastalıkların tedavisinde halen yaygın olarak kullanılmaktadır. Anti-TNF-α tedavisialan hastalarda tüberküloz ve bazı fırsatçı enfeksiyonların sıklığının arttığı bildirilmiştir. Bu çalışmada anti-TNF- α ajanları ile tedavi edilen hastalarda latent tüberküloz prevalansının araştırılması amaçlanmıştır.Materyal ve Metod: Çalışmaya Romatoloji polikliniğine başvuran ve anti-TNF-α tedavisi alan 83 hastaçalışmaya dahil edildi. Hastalara yapıldı ve akciğer grafisi çekildi.5 mm ve üzeri tuberkülin cilt testi (PPD)endurasyon saptanan hastalar latent tüberküloz olarak kabul edildi. Latent tüberküloz saptanan hastalaraizoniazid (INH) tedavisi 300 mg/gün olarak başlandı ve 9 ay sürdürüldü.Bulgular: Çalışmaya alınan 83 hastanın (25 kadın, 58 erkek) yaş ortalamaları 37,59±10,80 yıl olup,ortalama hastalık süresi 9,82 ± 7,08 yıl idi. Primer hastalık olarak AS (n=62), RA (n=16) ve PsA (n=5)mevcuttu. Hastalar farklı anti-TNF- α ajanlar (etanercept n=30, adalimumab n=30, infliksimab n=21 vegolimumab n=2) ile tedavi edilmişlerdi.PPD 83 hastanın 63'ünde (% 76) 5 mm ve üzeri olarak tespit edildi.INH profilaksisi PPD 5 mm'nin altında olup sağlık çalışanı olmak, geçirilmiş ile mikobakterium tüberkülozisenfeksiyon veya aile öyküsü gibi artmış tüberküloz riski olan 13 hastanın da dahil olduğu 76 hastayabaşlandı. endurasyonu ≥5 mm olan erkek hasta mevcudiyeti (%76) kadınlardan (%24) istatistiksel PPDolarak anlamlı derecede yüksek bulunmuştur (). p=0,026PPD endurasyonunun PPD ≥5 mm olduğu olgularda AS varlığı (n=51,%81),endurasyonu

🔖

Cite This Article

VURAL, M., ERHAN, B., BES, C., GÜNDÜZ, B. (2022). Tümör nekrozis faktör alfa antagonistleri ile tedavi edilen hastalarda latent tüberküloz prevelansı değerlendirilmesi. Harran Üniversitesi Tıp Fakültesi Dergisi, Cilt: 11 - Sayı: 1, 45–52. https://ajindex.com/articles/534126

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Yun JW, Lim SY, Suh GY, Chung MP, Kim H, Kwon OJ et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci 2007; 22(5):779-83
  2. Paluch-Oleś J, Magryś A, Kozioł-Montewka M, Koszarny A, Majdan M. Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-α agents. Arch Med Sci 2013; 9(1):112-7. 3)Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19:163-96
  3. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003; 42(5):617-21
  4. Voulgari PV. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Expert Rev Clin Immunol 2010; 6(5):721-33
  5. Schett G, Coates LC, Ash ZR, Finzel S, Conaghan PG. Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future. Arthritis Res Ther 2011 25; 13 Suppl 1:S4
  6. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60(10):800-5
  7. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, et al. BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52(6):1766-72
  8. Furst DE, Cush J, Kaufmann S, Siegel J, Kurth R. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis 2002; 61(2):62-3
  9. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48(8):2122-27
  10. Gómez-Reino JJ, Carmona L, Angel Descalzo M. BIOBADASER Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactiv